BAYN.DE Stock Risk & Deep Value Analysis
BAYN.DE
Healthcare • Drug Manufacturers - General
DVR Score
out of 10
What You Need to Know About BAYN.DE Stock
We analyzed BAYN.DE using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran BAYN.DE through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is BAYN.DE Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Low
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for BAYN.DE?
- ⚠
Unfavorable court rulings or increased provisions for Roundup litigation
- ⚠
Delays, execution failures, or shareholder dissent regarding strategic restructuring plans
- ⚠
Significant setbacks or failures in the pharmaceutical R&D pipeline
- ⚠
Economic downturns impacting agricultural commodity prices or consumer health spending
Unlock BAYN.DE Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does BAYN.DE (BAYN.DE) Do?
Market Cap
$33.17B
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
88,502
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, pain and cardiovascular risk prevention products, digestive health products, allergy products, and cold and cough products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
Visit BAYN.DE WebsiteIs BAYN.DE Stock Undervalued?
Unlock the full AI analysis for BAYN.DE
Get the complete DVR score, risk analysis, and more
Does BAYN.DE Have a Competitive Moat?
Sign in to unlockMoat Rating
🏰 Wide
Moat Trend
Stable
Moat Sources
4 Identified
Bayer's moat has historically been robust, built on decades of R&D, strong brands (e.g., Aspirin, established crop solutions), and global scale. However, the legal liabilities and significant debt levels are consuming capital, potentially limiting aggressive investment required to expand and defend this moat against emerging threats.
Moat Erosion Risks
- •Patent expirations on key pharmaceutical drugs and agrochemicals
- •Increased generic and biosimilar competition
- •Failure of new product development to offset mature portfolio declines
- •Ongoing legal and regulatory pressures impacting operational flexibility and capital allocation
BAYN.DE Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive BAYN.DE Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated Early May 2026)
- •Updates on ongoing Roundup litigation mediation and appeal processes
- •Further details or official announcements regarding the strategic review and potential asset divestitures/spin-offs
Medium-Term (6-18 months)
- •Finalization of a major Roundup litigation settlement or significant resolution
- •Formal announcement and execution plan for a major spin-off (e.g., Consumer Health or Crop Science division)
- •Key Phase 3 clinical trial readouts for promising pharmaceutical pipeline assets
Long-Term (18+ months)
- •Full realization of strategic restructuring benefits and sustained deleveraging
- •Successful integration of new product cycles in Pharma and Crop Science, driving organic growth
- •Re-rating of the stock multiple post-liabilities resolution, reflecting cleaner balance sheet and clearer divisional focus
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for BAYN.DE?
- ✓
Resolution of major Roundup litigation (settlements or favorable court rulings)
- ✓
Concrete announcements and successful execution of strategic spin-offs or divestitures
- ✓
Consistent and significant reduction in net debt and improved free cash flow
- ✓
Positive Phase 3 clinical trial results for key pipeline assets, signaling future pharma growth
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for BAYN.DE (BAYN.DE) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
